U.S. FDA approves Supernus' drug-device combination for Parkinson's disease
04/02/2025 14:15
Feb 4 (Reuters) - The U.S. Food and Drug Administration
has approved Supernus Pharmaceuticals' SUPN.O drug-device
combination to treat movement-related symptoms of Parkinson's
disease, the drugmaker said on Tuesday.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
((Puyaan.Singh@thomsonreuters.com;))
Recent news on Supernus Pharmaceuticals
See all newsHuron Consulting poised to hit fresh record ahead of S&P SmallCap addition
Brief: S&P Dow Jones Indices Msg Rangers And Huron Consulting Group Set To Join S&P Smallcap 600
Brief: Supernus Pharmaceuticals Says FDA Grants Seven Years Orphan-Drug Exclusivity For Onapgo
Supernus Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary
U.S. STOCKS ON THE MOVE -Micron Technology, Ares Management, Boeing